Clinical Scorecard: Liquid Biopsy Predicts Early Lung Cancer Relapse

At a Glance

Key Highlights

• The retrospective study analyzed 331 blood samples from 42 patients with stage IA lung adenocarcinoma.
• The WGS-based approach predicted recurrence with 75% sensitivity and 83% specificity.
• Nine of 12 patients who experienced recurrence had detectable ctDNA.
• In six patients, a positive ctDNA test preceded clinical or imaging confirmation by a median of 16.7 months.
• The study requires prospective validation; integration with imaging and effects on patient outcomes remain to be established.

Guideline-Based Recommendations

Diagnosis

• The study used WGS of each patient's original tumor and matched normal tissue to establish an individual genetic fingerprint, then searched follow-up blood samples for matching ctDNA.

Management

• The article reports that ctDNA analysis could help identify patients who may benefit from additional treatment, but does not establish a treatment recommendation.
• Further studies are needed to determine how molecular monitoring should be integrated with imaging.

Monitoring & Follow-up

• Current postoperative follow-up relies primarily on imaging.
• The study evaluated ctDNA testing in blood samples collected during treatment and follow-up.

Risks

• The evidence comes from a small retrospective study and requires prospective validation.
• The article identifies sample collection, testing costs, and use of routinely processed pathology specimens as challenges.
• Whether earlier molecular detection improves patient outcomes has not been established.

Patient & Prescribing Data

The retrospective study included 42 patients with stage IA lung adenocarcinoma; 12 experienced recurrence.

The article describes a potential role for ctDNA testing in identifying residual disease and informing surveillance or intervention, but provides no established prescribing regimen or treatment-effect data.

Clinical Best Practices

• Interpret the reported performance in the context of the study's small, retrospective cohort.
• Do not treat the reported lead time as evidence that earlier detection improves outcomes; the article states that this requires further study.
• Consider that WGS distinguished recurrent disease from a second primary lung tumor in the study, a distinction that can be difficult using conventional pathology alone.

Related Resources & Content

• The Journal of Molecular Diagnostics study described in the article